Just a few years since pioneering a Covid-19 vaccine, Moderna faces a hostile political environment and a looming patent problem. We recently compiled a list of the 12 Most Promising Biotech ...

Moderna's plans include a $1.1 billion reduction in R&D expenses by 2027 to a range of $3.6 billion to $3.8 billion. Rather than spending to explore new products, the company will shift its focus ...